Catalent Pharma Solutions, Inc. (CTLT)
Dec 18, 2024 - CTLT was delisted (reason: acquired by Novo Holdings)
63.48
0.00 (0.00%)
Inactive · Last trade price on Dec 17, 2024

Company Description

Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products.

The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials.

This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products.

Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising prescription and consumer health products.

This segment provides formulation, development, and manufacturing services for soft gelatin capsules, modified release, and immediate release solid oral technology products; and fast-dissolve tablets, and proprietary and conventional controlled release products.

The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for prefilled syringes and other injectable formats; blow-fill-seal unit dose development and manufacturing services; and biologic cell line development and manufacturing services.

It serves pharmaceutical and biotechnology, and consumer health companies. The company was incorporated in 1989 and is headquartered in Somerset, New Jersey.

Catalent Pharma Solutions, Inc. operates as a subsidiary of Catalent, Inc.

Catalent Pharma Solutions, Inc.
Catalent logo
CountryUnited States
Founded1989
IPO DateJul 31, 2014
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees17,800
CEOAlessandro Maselli

Contact Details

Address:
14 Schoolhouse Road
Somerset, Delaware 08873
United States
Phone732 537 6200
Websitecatalent.com

Stock Details

Ticker SymbolCTLT
ExchangeNYSE
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001596783
CUSIP Number148806102
ISIN NumberUS1488061029
Employer ID20-8737688
SIC Code2834

Key Executives

NamePosition
Alessandro MaselliPresident, Chief Executive Officer and Director
John J. Greisch M.B.A.Executive Chairman of the Board
Matti M. MasanovichSenior Vice President and Chief Financial Officer
Lisa EvoliSenior Vice President and Chief Human Resources Officer
Ricky HopsonPresident, Division Head for BioProduct Delivery and Chief of Staff
David McErlaneGroup President of Biologics Segment
Michael J. Hatzfeld Jr.Vice President and Chief Accounting Officer
Charles LickfoldSenior Vice President and Chief Information Officer
Paul SurdezVice President of Investor Relations
Joseph A. Ferraro J.D.Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Latest SEC Filings

DateTypeTitle
Dec 18, 2024POSASRFiling
Dec 18, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 18, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 18, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Dec 18, 20248-KCurrent Report
Dec 18, 202425-NSEFiling
Dec 16, 20248-KCurrent Report
Dec 6, 20248-KCurrent Report
Nov 14, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals